Chondrocyte membrane-camouflaged selenium nanoplatform with dual targeting for mitochondrial restoration and osteoarthritis therapy.

Zhang Z, Du Q, Zhu Z, Zhu Z, He J, Xin Z, Deng J

Journal of controlled release : official journal of the Controlled Release Society12 Aug 2026

PMID42586485DOI10.1016/j.jconrel.2026.115257PepBankPUB-42586485

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

01AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Pharmacokinetics
After intra-articular injection, the CM@SS31-Se nanoplatform showed prolonged joint retention for up to 14 days.
In plain wordsAfter injection into the joint, the nanoplatform stayed in the joint for up to 14 days in animals.
Peptide
Elamipretide (SS-31)
Outcome
Not applicableJoint retention
Study
n: not reported in source
Outcome group
Pharmacokinetics · Musculoskeletal
Source sentences
Summary
Following intra-articular injection, the nanoplatform demonstrates prolonged joint retention up to 14 days with favorable biocompatibility.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4258648501
02AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Safety outcome
After intra-articular injection, the CM@SS31-Se nanoplatform showed favorable biocompatibility.
In plain wordsAfter injection into the joint, the nanoplatform showed favorable biocompatibility in animals.
Peptide
Elamipretide (SS-31)
Outcome
Not applicableBiocompatibility
Study
n: not reported in source
Outcome group
Adverse events · Musculoskeletal
Source sentences
Summary
Following intra-articular injection, the nanoplatform demonstrates prolonged joint retention up to 14 days with favorable biocompatibility.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4258648508
03LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Mechanism
In degenerative chondrocytes, the CM@SS31-Se nanoplatform restored mitochondrial membrane potential.
In plain wordsIn cartilage cells, the nanoplatform restored mitochondrial membrane potential.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseMitochondrial membrane potential
Study
n: not reported in source
degenerative chondrocytes
Outcome group
Mitochondrial function · Musculoskeletal
Source sentences
Summary
restore mitochondrial membrane potential and ATP synthesis
1 context sentence(design, population, supporting numbers)
Summary · context
Here, we develop a biomimetic nanoplatform (CM@SS31-Se) with dual targeting capability.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4258648502
04LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Mechanism
In degenerative chondrocytes, the CM@SS31-Se nanoplatform restored ATP synthesis.
In plain wordsIn cartilage cells, the nanoplatform restored energy (ATP) production.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseATP synthesis
Study
n: not reported in source
degenerative chondrocytes
Outcome group
Mitochondrial function · Musculoskeletal
Source sentences
Summary
restore mitochondrial membrane potential and ATP synthesis
1 context sentence(design, population, supporting numbers)
Summary · context
Here, we develop a biomimetic nanoplatform (CM@SS31-Se) with dual targeting capability.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4258648503
05LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Mechanism
In degenerative chondrocytes, the CM@SS31-Se nanoplatform upregulated the anabolic markers SOX9, Col II and Aggrecan.
In plain wordsIn cartilage cells, the nanoplatform raised markers of cartilage building.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseAnabolic markers (SOX9, Col II, Aggrecan)
Study
n: not reported in source
degenerative chondrocytes
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
upregulate anabolic markers (SOX9, Col II, Aggrecan)
1 context sentence(design, population, supporting numbers)
Summary · context
Here, we develop a biomimetic nanoplatform (CM@SS31-Se) with dual targeting capability.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4258648504
06LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Mechanism
In degenerative chondrocytes, the CM@SS31-Se nanoplatform downregulated MMP13.
In plain wordsIn cartilage cells, the nanoplatform lowered MMP13, an enzyme that breaks down cartilage.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseMMP13 expression
Study
n: not reported in source
degenerative chondrocytes
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
downregulate MMP13 and pro-inflammatory mediators, ultimately promoting the restoration of a regenerative phenotype in degenerative chondrocytes.
1 context sentence(design, population, supporting numbers)
Summary · context
Here, we develop a biomimetic nanoplatform (CM@SS31-Se) with dual targeting capability.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4258648505
07LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Mechanism
In degenerative chondrocytes, the CM@SS31-Se nanoplatform downregulated pro-inflammatory mediators.
In plain wordsIn cartilage cells, the nanoplatform lowered inflammatory signals.
Peptide
Elamipretide (SS-31)
Outcome
DecreasePro-inflammatory mediators
Study
n: not reported in source
degenerative chondrocytes
Outcome group
Inflammation markers · Musculoskeletal
Source sentences
Summary
downregulate MMP13 and pro-inflammatory mediators, ultimately promoting the restoration of a regenerative phenotype in degenerative chondrocytes.
1 context sentence(design, population, supporting numbers)
Summary · context
Here, we develop a biomimetic nanoplatform (CM@SS31-Se) with dual targeting capability.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4258648506
08LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Efficacy outcome
In degenerative chondrocytes, the CM@SS31-Se nanoplatform promoted restoration of a regenerative phenotype.
In plain wordsIn cartilage cells, the nanoplatform helped restore a cell state able to rebuild cartilage.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseRegenerative phenotype
Study
n: not reported in source
degenerative chondrocytes
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
ultimately promoting the restoration of a regenerative phenotype in degenerative chondrocytes.
1 context sentence(design, population, supporting numbers)
Summary · context
Here, we develop a biomimetic nanoplatform (CM@SS31-Se) with dual targeting capability.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4258648507

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 08:19 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.